{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T19:13:57Z","timestamp":1793042037268,"version":"4.5.0"},"reference-count":217,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advanced Drug Delivery Reviews"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.addr.2026.115957","type":"journal-article","created":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T14:53:52Z","timestamp":1786805632000},"page":"115957","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Bioactive nanomedicines for multidrug-resistant colorectal cancer: Actionable mechanisms, emerging particle classes, and translational barriers"],"prefix":"10.1016","volume":"238","author":[{"given":"Milad","family":"Rasouli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Babaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Fallahhosseini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adeleh","family":"Divsalar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.addr.2026.115957_bb0005","article-title":"Global cancer statistics 2024: GLOBOCAN estimates of incidence and mortality worldwide for 34 cancers in 186 countries","volume":"76","author":"Sung","year":"2026","journal-title":"CA Cancer J. Clin."},{"issue":"12","key":"10.1016\/j.addr.2026.115957_bb0010","article-title":"Molecular and cellular paradigms of multidrug resistance in cancer","volume":"5","author":"Vaidya","year":"2022","journal-title":"Cancer Rep."},{"issue":"6","key":"10.1016\/j.addr.2026.115957_bb0015","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.annonc.2026.03.005","article-title":"Metastatic colorectal cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"37","author":"Cremolini","year":"2026","journal-title":"Ann. Oncol."},{"issue":"4","key":"10.1016\/j.addr.2026.115957_bb0020","doi-asserted-by":"crossref","DOI":"10.3390\/app13042667","article-title":"Vegetal-derived bioactive compounds as multidrug resistance modulators in colorectal cancer","volume":"13","author":"Qui\u00f1onero","year":"2023","journal-title":"Appl. Sci."},{"issue":"9","key":"10.1016\/j.addr.2026.115957_bb0025","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1021\/acsptsci.4c00462","article-title":"Colon-targeted sustained-release combinatorial 5-fluorouracil and quercetin poly(lactic-co-glycolic) acid (PLGA) nanoparticles show enhanced apoptosis and minimal tumor drug resistance for their potential use in colon cancer","volume":"7","author":"Abosalha","year":"2024","journal-title":"ACS Pharmacol. & Translational Sci."},{"key":"10.1016\/j.addr.2026.115957_bb0030","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2025.1582659","article-title":"Targeted and intelligent nano-drug delivery systems for colorectal cancer treatment","volume":"13","author":"Chai","year":"2025","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/j.addr.2026.115957_bb0035","doi-asserted-by":"crossref","first-page":"1340401","DOI":"10.3389\/fphar.2023.1340401","article-title":"Deciphering treatment resistance in metastatic colorectal cancer: roles of drug transports, EGFR mutations, and HGF\/c-MET signaling","volume":"14","author":"Albadari","year":"2024","journal-title":"Front. Pharmacol."},{"issue":"3","key":"10.1016\/j.addr.2026.115957_bb0040","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.apsb.2022.10.002","article-title":"Progress in the studies on the molecular mechanisms associated with multidrug resistance in cancers","volume":"13","author":"Zhang","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"issue":"6","key":"10.1016\/j.addr.2026.115957_bb0810","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1002\/ijc.20032","article-title":"ABCG2 overexpression in colon cancer cells resistant to SN38 and in irinotecan-treated metastases","volume":"109","author":"Candeil","year":"2004","journal-title":"Int. J. Cancer"},{"issue":"11","key":"10.1016\/j.addr.2026.115957_bb0815","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.7150\/jca.12606","article-title":"ABC-transporter expression does not correlate with response to irinotecan in patients with metastatic colorectal cancer","volume":"6","author":"Trumpi","year":"2015","journal-title":"J. Cancer"},{"issue":"9","key":"10.1016\/j.addr.2026.115957_bb0820","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.3390\/ijms18091926","article-title":"Implications of ABCG2 expression on irinotecan treatment of colorectal cancer patients: a review","volume":"18","author":"Nielsen","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.addr.2026.115957_bb0825","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.canlet.2020.02.007","article-title":"IRE1\u03b1-targeting downregulates ABC transporters and overcomes drug resistance of colon cancer cells","volume":"476","author":"Gao","year":"2020","journal-title":"Cancer Lett."},{"issue":"4","key":"10.1016\/j.addr.2026.115957_bb0830","doi-asserted-by":"crossref","first-page":"977","DOI":"10.3390\/cancers12040977","article-title":"An explorative analysis of ABCG2\/TOP-1 mRNA expression as a biomarker test for FOLFIRI treatment in stage III colon cancer patients: results from retrospective analyses of the PETACC-3 trial","volume":"12","author":"Stenvang","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"6","key":"10.1016\/j.addr.2026.115957_bb0835","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1111\/cas.15761","article-title":"STAT3 regulates 5-Fu resistance in human colorectal cancer cells by promoting Mcl-1\u2013dependent cytoprotective autophagy","volume":"114","author":"Yue","year":"2023","journal-title":"Cancer Sci."},{"issue":"6","key":"10.1016\/j.addr.2026.115957_bb0840","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1158\/1078-0432.CCR-03-0362","article-title":"Characterization of p53 wild-type and null isogenic colorectal cancer cell lines resistant to 5-fluorouracil, oxaliplatin, and irinotecan","volume":"10","author":"Boyer","year":"2004","journal-title":"Clin. Cancer Res."},{"issue":"7","key":"10.1016\/j.addr.2026.115957_bb0845","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1097\/CAD.0b013e328353f8c7","article-title":"Resistance of colon cancer to 5-fluorouracil may be overcome by combination with chloroquine: an in vivo study","volume":"23","author":"Sasaki","year":"2012","journal-title":"Anticancer Drugs"},{"issue":"3","key":"10.1016\/j.addr.2026.115957_bb0850","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.cell.2017.07.008","article-title":"Fusobacterium nucleatum promotes chemoresistance to colorectal cancer by modulating autophagy","volume":"170","author":"Yu","year":"2017","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.addr.2026.115957_bb0855","doi-asserted-by":"crossref","first-page":"5321","DOI":"10.1038\/s41467-020-19173-2","article-title":"5-FU promotes stemness of colorectal cancer via p53-mediated WNT\/\u03b2-catenin pathway activation","volume":"11","author":"Cho","year":"2020","journal-title":"Nat. Commun."},{"issue":"8","key":"10.1016\/j.addr.2026.115957_bb0860","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.biopha.2013.08.001","article-title":"Lgr5 promotes cancer stemness and confers chemoresistance through ABCB1 in colorectal cancer","volume":"67","author":"Liu","year":"2013","journal-title":"Biomed. Pharmacother."},{"issue":"11","key":"10.1016\/j.addr.2026.115957_bb0865","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1007\/s00384-013-1721-x","article-title":"Overexpression of Lgr5 correlates with resistance to 5-FU-based chemotherapy in colorectal cancer","volume":"28","author":"Hsu","year":"2013","journal-title":"Int. J. Color. Dis."},{"key":"10.1016\/j.addr.2026.115957_bb0870","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.2147\/OTT.S241367","article-title":"FOXC2 promotes oxaliplatin resistance by inducing epithelial-mesenchymal transition via MAPK\/ERK signaling in colorectal cancer","volume":"13","author":"Chen","year":"2020","journal-title":"Onco. Targets Ther."},{"issue":"1","key":"10.1016\/j.addr.2026.115957_bb0875","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/s41419-025-07855-y","article-title":"Modeling oxaliplatin resistance in colorectal cancer reveals a SERPINE1-based gene signature (RESIST-M) and therapeutic strategies for pro-metastatic CMS4 subtype","volume":"16","author":"Wong","year":"2025","journal-title":"Cell Death Dis."},{"issue":"1","key":"10.1016\/j.addr.2026.115957_bb0880","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1186\/s12967-025-07380-8","article-title":"Dynamic remodelling of epithelial plasticity in colorectal cancer from single-cell and spatially resolved perspectives","volume":"23","author":"Xu","year":"2025","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.addr.2026.115957_bb0080","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.924290","article-title":"Autophagy: a versatile player in the progression of colorectal cancer and drug resistance","volume":"12","author":"Manzoor","year":"2022","journal-title":"Front. Oncol."},{"issue":"10","key":"10.1016\/j.addr.2026.115957_bb0885","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1016\/j.ymthe.2019.05.017","article-title":"Hypoxia induces drug resistance in colorectal cancer through the HIF-1\u03b1\/miR-338-5p\/IL-6 feedback loop","volume":"27","author":"Xu","year":"2019","journal-title":"Mol. Ther."},{"issue":"37","key":"10.1016\/j.addr.2026.115957_bb0890","doi-asserted-by":"crossref","first-page":"59766","DOI":"10.18632\/oncotarget.11121","article-title":"Carcinoma-associated fibroblasts affect sensitivity to oxaliplatin and 5FU in colorectal cancer cells","volume":"7","author":"Gon\u00e7alves-Ribeiro","year":"2016","journal-title":"Oncotarget"},{"issue":"13","key":"10.1016\/j.addr.2026.115957_bb0895","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1084\/jem.20131195","article-title":"Chemotherapy activates cancer-associated fibroblasts to maintain colorectal cancer-initiating cells by IL-17A","volume":"210","author":"Lotti","year":"2013","journal-title":"J. Exp. Med."},{"issue":"14","key":"10.1016\/j.addr.2026.115957_bb0900","doi-asserted-by":"crossref","first-page":"3932","DOI":"10.7150\/thno.25541","article-title":"Carcinoma-associated fibroblasts promote the stemness and chemoresistance of colorectal cancer by transferring exosomal lncRNA H19","volume":"8","author":"Ren","year":"2018","journal-title":"Theranostics"},{"issue":"1","key":"10.1016\/j.addr.2026.115957_bb0905","doi-asserted-by":"crossref","DOI":"10.1080\/19490976.2024.2333790","article-title":"Fusobacterium nucleatum induces chemoresistance in colorectal cancer by inhibiting pyroptosis via the hippo pathway","volume":"16","author":"Wang","year":"2024","journal-title":"Gut Microbes"},{"issue":"7","key":"10.1016\/j.addr.2026.115957_bb0910","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1007\/s12094-019-02237-1","article-title":"Novel exosomal miR-46146 transfer oxaliplatin chemoresistance in colorectal cancer","volume":"22","author":"Xu","year":"2020","journal-title":"Clin. Transl. Oncol."},{"issue":"44","key":"10.1016\/j.addr.2026.115957_bb0045","doi-asserted-by":"crossref","first-page":"31761","DOI":"10.1074\/jbc.M113.514091","article-title":"P-glycoprotein mediates drug resistance via a novel mechanism involving lysosomal sequestration","volume":"288","author":"Yamagishi","year":"2013","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.addr.2026.115957_bb0050","article-title":"Dihydromyricetin reverses MRP2-induced multidrug resistance by preventing NF-\u03baB-Nrf2 signaling in colorectal cancer cell","volume":"82","author":"Wang","year":"2021","journal-title":"Corrigendum Phytomedicine."},{"issue":"11","key":"10.1016\/j.addr.2026.115957_bb0055","doi-asserted-by":"crossref","DOI":"10.3390\/ph16111595","article-title":"Imperatorin restores chemosensitivity of multidrug-resistant cancer cells by antagonizing ABCG2-mediated drug transport","volume":"16","author":"Wu","year":"2023","journal-title":"Pharmaceuticals"},{"issue":"5922","key":"10.1016\/j.addr.2026.115957_bb0790","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1126\/science.1168750","article-title":"Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding","volume":"323","author":"Aller","year":"2009","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.addr.2026.115957_bb0795","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1002\/pro.2387","article-title":"Refined structures of mouse P-glycoprotein","volume":"23","author":"Li","year":"2014","journal-title":"Protein Sci."},{"issue":"6428","key":"10.1016\/j.addr.2026.115957_bb0800","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1126\/science.aav7102","article-title":"Structural insight into substrate and inhibitor discrimination by human P-glycoprotein","volume":"363","author":"Alam","year":"2019","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.addr.2026.115957_bb0805","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/s44318-025-00361-z","article-title":"Structural insights into binding-site access and ligand recognition by human ABCB1","volume":"44","author":"Kurre","year":"2025","journal-title":"EMBO J."},{"key":"10.1016\/j.addr.2026.115957_bb0060","doi-asserted-by":"crossref","first-page":"61","DOI":"10.2147\/PGPM.S108656","article-title":"UGT1A1 polymorphisms in cancer: impact on irinotecan treatment","volume":"10","author":"Takano","year":"2017","journal-title":"Pharmacogenomics Personalized Med."},{"issue":"10","key":"10.1016\/j.addr.2026.115957_bb0065","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20200576","article-title":"Association of UGT1A1* 6 polymorphism with irinotecan-based chemotherapy reaction in colorectal cancer patients: a systematic review and a meta-analysis","volume":"40","author":"Zhu","year":"2020","journal-title":"Biosci. Rep."},{"issue":"2","key":"10.1016\/j.addr.2026.115957_bb0070","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41573-020-0090-8","article-title":"Engineering precision nanoparticles for drug delivery","volume":"20","author":"Mitchell","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1","key":"10.1016\/j.addr.2026.115957_bb0075","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-32092-8","article-title":"Different impacts of TP53 mutations on cell cycle-related gene expression among cancer types","volume":"13","author":"Sasaki","year":"2023","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.addr.2026.115957_bb0085","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/s41419-021-04334-y","article-title":"MCL1 nuclear translocation induces chemoresistance in colorectal carcinoma","volume":"13","author":"Fu","year":"2022","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.addr.2026.115957_bb0090","article-title":"Stress-induced CD55 supports homologous recombination capacity and drives oxaliplatin resistance in colorectal cancer","author":"Wang","year":"2026","journal-title":"Cell Commun. Signal."},{"issue":"1","key":"10.1016\/j.addr.2026.115957_bb0095","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s10555-023-10126-x","article-title":"Resveratrol as sensitizer in colorectal cancer plasticity","volume":"43","author":"Brockmueller","year":"2024","journal-title":"Cancer Metastasis Rev."},{"issue":"9","key":"10.1016\/j.addr.2026.115957_bb0100","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.1021\/acs.jafc.8b06665","article-title":"(\u2212)-epigallocatechin Gallate (EGCG) enhances the sensitivity of colorectal cancer cells to 5-FU by inhibiting GRP78\/NF-\u03baB\/miR-155-5p\/MDR1 pathway","volume":"67","author":"La","year":"2019","journal-title":"J. Agric. Food Chem."},{"issue":"1","key":"10.1016\/j.addr.2026.115957_bb0105","first-page":"7099589","article-title":"EGCG enhances the chemosensitivity of colorectal cancer to irinotecan through GRP78-mediated endoplasmic reticulum stress","volume":"2022","author":"Wu","year":"2022","journal-title":"J. Oncol."},{"issue":"8","key":"10.1016\/j.addr.2026.115957_bb0110","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25084140","article-title":"The impact of cancer stem cells in colorectal cancer","volume":"25","author":"Radu","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"38","key":"10.1016\/j.addr.2026.115957_bb0115","doi-asserted-by":"crossref","first-page":"4990","DOI":"10.1038\/onc.2016.29","article-title":"Topoisomerase II\u03b1 mediates TCF-dependent epithelial\u2013mesenchymal transition in colon cancer","volume":"35","author":"Zhou","year":"2016","journal-title":"Oncogene"},{"key":"10.1016\/j.addr.2026.115957_bb0120","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.2147\/OTT.S82835","article-title":"Hypoxia-inducible factor-1\u03b1 induces multidrug resistance protein in colon cancer","volume":"8","author":"Lv","year":"2015","journal-title":"Onco. Targets. Ther."},{"issue":"6","key":"10.1016\/j.addr.2026.115957_bb0125","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1021\/mp200292c","article-title":"Drug resistance and cellular adaptation to tumor acidic pH microenvironment","volume":"8","author":"Wojtkowiak","year":"2011","journal-title":"Mol. Pharm."},{"issue":"7","key":"10.1016\/j.addr.2026.115957_bb0130","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.3390\/cancers17071098","article-title":"Addressing challenges in targeted therapy for metastatic colorectal cancer","volume":"17","author":"El Hage","year":"2025","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.addr.2026.115957_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2026.114993","article-title":"Toward targeting the untargetable: a non-canonical EGFR-peptide-drug conjugate achieves potent antitumor activity in KRAS-mutant CRC","volume":"395","author":"Ayali","year":"2026","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2026.115957_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2025.104775","article-title":"Immunotherapy in microsatellite-stable colorectal cancer: strategies to overcome resistance","volume":"212","author":"Chen","year":"2025","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.addr.2026.115957_bb0145","doi-asserted-by":"crossref","DOI":"10.1158\/2159-8290.CD-26-0542","article-title":"Mismatch repair-proficient colorectal cancer can evade immune surveillance through an intrinsic suppressive program","author":"Cattaneo","year":"2026","journal-title":"Cancer Discov."},{"key":"10.1016\/j.addr.2026.115957_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2024.102700","article-title":"Current advances in targeted therapy for metastatic colorectal cancer\u2013clinical translation and future directions","volume":"125","author":"Johnson","year":"2024","journal-title":"Cancer Treat. Rev."},{"issue":"1","key":"10.1016\/j.addr.2026.115957_bb0155","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41571-024-00965-0","article-title":"Late-line options for patients with metastatic colorectal cancer: a review and evidence-based algorithm","volume":"22","author":"Ciraci","year":"2025","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.addr.2026.115957_bb0160","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10081948","article-title":"Plant-derived bioactive compounds in colorectal cancer: insights from combined regimens with conventional chemotherapy to overcome drug-resistance","volume":"10","author":"Gavrilas","year":"2022","journal-title":"Biomedicines"},{"issue":"1","key":"10.1016\/j.addr.2026.115957_bb0165","doi-asserted-by":"crossref","DOI":"10.1038\/srep24675","article-title":"Curcumin mediates oxaliplatin-acquired resistance reversion in colorectal cancer cell lines through modulation of CXC-chemokine\/NF-\u03baB signalling pathway","volume":"6","author":"Ruiz de Porras","year":"2016","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.addr.2026.115957_bb0915","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0085397","article-title":"Curcumin chemosensitizes 5-fluorouracil resistant MMR-deficient human colon cancer cells in high density cultures","volume":"9","author":"Shakibaei","year":"2014","journal-title":"PloS One"},{"issue":"12","key":"10.1016\/j.addr.2026.115957_bb0235","doi-asserted-by":"crossref","first-page":"9499","DOI":"10.1007\/s13277-015-3636-3","article-title":"Resveratrol induces AMPK-dependent MDR1 inhibition in colorectal cancer HCT116\/L-OHP cells by preventing activation of NF-\u03baB signaling and suppressing cAMP-responsive element transcriptional activity","volume":"36","author":"Wang","year":"2015","journal-title":"Tumour Biol."},{"issue":"13","key":"10.1016\/j.addr.2026.115957_bb0920","doi-asserted-by":"crossref","first-page":"16158","DOI":"10.18632\/oncotarget.7567","article-title":"Epigallocatechin-3-gallate targets cancer stem-like cells and enhances 5-fluorouracil chemosensitivity in colorectal cancer","volume":"7","author":"Toden","year":"2016","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.addr.2026.115957_bb0185","doi-asserted-by":"crossref","DOI":"10.4081\/ejh.2023.3719","article-title":"Quercetin reverses 5-fluorouracil resistance in colon cancer cells by modulating the NRF2\/HO-1 pathway","volume":"67","author":"Tang","year":"2023","journal-title":"Eur. J. Histochem."},{"key":"10.1016\/j.addr.2026.115957_bb0925","article-title":"\u03b2-Elemene reverses the resistance of p53-deficient colorectal cancer cells to 5-fluorouracil by inducing pro-death autophagy and cyclin D3-dependent cycle arrest","volume":"8","author":"Zhang","year":"2020","journal-title":"Front. Bioeng. Biotechnol."},{"issue":"3","key":"10.1016\/j.addr.2026.115957_bb0215","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1097\/CAD.0000000000000459","article-title":"Dihydromyricetin reverses MRP2-mediated MDR and enhances anticancer activity induced by oxaliplatin in colorectal cancer cells","volume":"28","author":"Wang","year":"2017","journal-title":"Anticancer Drugs"},{"issue":"1","key":"10.1016\/j.addr.2026.115957_bb0220","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1038\/s41598-019-38667-8","article-title":"Identification of MRP2 as a targetable factor limiting oxaliplatin accumulation and response in gastrointestinal cancer","volume":"9","author":"Myint","year":"2019","journal-title":"Sci. Rep."},{"issue":"6","key":"10.1016\/j.addr.2026.115957_bb0205","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1002\/jcb.25451","article-title":"Evodiamine suppresses ABCG2 mediated drug resistance by inhibiting the p50\/p65 NF-\u03baB pathway in colorectal cancer","volume":"117","author":"Sui","year":"2016","journal-title":"J. Cell. Biochem."},{"issue":"11","key":"10.1016\/j.addr.2026.115957_bb0210","doi-asserted-by":"crossref","DOI":"10.1002\/jbt.70541","article-title":"Evodiamine enhances chemosensitivity in colorectal cancer by targeting ribonucleotide reductase M2","volume":"39","author":"Chen","year":"2025","journal-title":"J. Biochem. Mol. Toxicol."},{"issue":"5","key":"10.1016\/j.addr.2026.115957_bb0930","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1002\/ddr.22067","article-title":"Dihydroartemisinin inhibited stem cell-like properties and enhanced oxaliplatin sensitivity of colorectal cancer via AKT\/mTOR signaling","volume":"84","author":"Wang","year":"2023","journal-title":"Drug Dev. Res."},{"issue":"2","key":"10.1016\/j.addr.2026.115957_bb0225","first-page":"2366","article-title":"Gambogic acid reverses oxaliplatin resistance in colorectal cancer by increasing intracellular platinum levels","volume":"16","author":"Wang","year":"2018","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.addr.2026.115957_bb0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2026.101445","article-title":"Targeting LIG1 to overcome oxaliplatin resistance by inducing PANoptosis in colorectal cancer","volume":"88","author":"Gao","year":"2026","journal-title":"Drug Resist. Updat."},{"issue":"5","key":"10.1016\/j.addr.2026.115957_bb0935","first-page":"1851","article-title":"Emodin reverses 5-Fu resistance in human colorectal cancer via downregulation of PI3K\/Akt signaling pathway","volume":"12","author":"Li","year":"2020","journal-title":"Am. J. Transl. Res."},{"issue":"10","key":"10.1016\/j.addr.2026.115957_bb0940","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpha.2025.101343","article-title":"Emodin is a novel phosphatidylethanolamine anabolism inhibitor that reprograms lipid metabolism to overcome 5-fluorouracil resistance in colorectal cancer","volume":"15","author":"Chen","year":"2025","journal-title":"J Pharm Anal"},{"issue":"12","key":"10.1016\/j.addr.2026.115957_bb0240","doi-asserted-by":"crossref","first-page":"5574","DOI":"10.7150\/thno.70754","article-title":"Microbial metabolite restricts 5-fluorouracil-resistant colonic tumor progression by sensitizing drug transporters via regulation of the FOXO3-FOXM1 axis","volume":"12","author":"Ghosh","year":"2022","journal-title":"Theranostics"},{"issue":"1","key":"10.1016\/j.addr.2026.115957_bb0170","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s43440-024-00652-y","article-title":"A comprehensive update on the potential of curcumin to enhance chemosensitivity in colorectal cancer","volume":"77","author":"Shadnoush","year":"2025","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.addr.2026.115957_bb0175","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2019.00487","article-title":"Reversal of multidrug resistance in cancer by multi-functional flavonoids","volume":"9","author":"Ye","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.addr.2026.115957_bb0180","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jare.2024.01.005","article-title":"Resveratrol and p53: how are they involved in CRC plasticity and apoptosis?","volume":"66","author":"Brockmueller","year":"2024","journal-title":"J. Adv. Res."},{"issue":"1","key":"10.1016\/j.addr.2026.115957_bb0190","first-page":"9","article-title":"\u03b2-Elemene induces apoptosis and autophagy in colorectal cancer cells through regulating the ROS\/AMPK\/mTOR pathway","volume":"20","author":"Guo-Yu","year":"2022","journal-title":"Chin. J. Nat. Med."},{"issue":"11","key":"10.1016\/j.addr.2026.115957_bb0195","doi-asserted-by":"crossref","first-page":"5107","DOI":"10.7150\/thno.44705","article-title":"Combinative treatment of \u03b2-elemene and cetuximab is sensitive to KRAS mutant colorectal cancer cells by inducing ferroptosis and inhibiting epithelial-mesenchymal transformation","volume":"10","author":"Chen","year":"2020","journal-title":"Theranostics"},{"issue":"17","key":"10.1016\/j.addr.2026.115957_bb0200","doi-asserted-by":"crossref","first-page":"5377","DOI":"10.3390\/molecules26175377","article-title":"Plant flavonoids: chemical characteristics and biological activity","volume":"26","author":"Dias","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.addr.2026.115957_bb0245","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.106991","article-title":"Curcumin may be a potential adjuvant treatment drug for colon cancer by targeting CD44","volume":"88","author":"Fan","year":"2020","journal-title":"Int. Immunopharmacol."},{"issue":"1","key":"10.1016\/j.addr.2026.115957_bb0250","first-page":"53","article-title":"Phase I pharmacokinetic study of tea polyphenols following single-dose administration of epigallocatechin gallate and polyphenon E","volume":"10","author":"Chow","year":"2001","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"issue":"2","key":"10.1016\/j.addr.2026.115957_bb0255","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1177\/147323000303100205","article-title":"A single ascending dose study of epigallocatechin gallate in healthy volunteers","volume":"31","author":"Ullmann","year":"2003","journal-title":"J. Int. Med. Res."},{"issue":"1","key":"10.1016\/j.addr.2026.115957_bb0260","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1158\/1055-9965.120.14.1","article-title":"Consumption of the putative chemopreventive agent curcumin by cancer patients: assessment of curcumin levels in the colorectum and their pharmacodynamic consequences","volume":"14","author":"Garcea","year":"2005","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"issue":"9","key":"10.1016\/j.addr.2026.115957_bb0265","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1158\/1940-6207.CAPR-11-0148","article-title":"Phase I randomized, double-blind pilot study of micronized resveratrol (SRT501) in patients with hepatic metastases - safety, pharmacokinetics, and pharmacodynamics","volume":"4","author":"Howells","year":"2011","journal-title":"Cancer Prev. Res."},{"issue":"5","key":"10.1016\/j.addr.2026.115957_bb0270","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1177\/00912700122010366","article-title":"Pharmacokinetics and bioavailability of quercetin glycosides in humans","volume":"41","author":"Graefe","year":"2001","journal-title":"J. Clin. Pharmacol."},{"issue":"1","key":"10.1016\/j.addr.2026.115957_bb0775","doi-asserted-by":"crossref","first-page":"164","DOI":"10.3892\/etm.2015.2895","article-title":"Bioavailability and safety study of resveratrol 500 mg tablets in healthy male and female volunteers","volume":"11","author":"Sergides","year":"2016","journal-title":"Exp. Ther. Med."},{"issue":"6","key":"10.1016\/j.addr.2026.115957_bb0770","first-page":"535","article-title":"Chemopreventive efficacy and pharmacokinetics of curcumin in the min\/+ mouse, a model of familial adenomatous polyposis","volume":"11","author":"Perkins","year":"2002","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"issue":"10","key":"10.1016\/j.addr.2026.115957_bb0945","doi-asserted-by":"crossref","first-page":"6817","DOI":"10.1002\/jcp.29576","article-title":"Hyaluronic acid-decorated liposomal nanoparticles for targeted delivery of 5-fluorouracil into HT-29 colorectal cancer cells","volume":"235","author":"Mansoori","year":"2020","journal-title":"J. Cell. Physiol."},{"issue":"9","key":"10.1016\/j.addr.2026.115957_bb0950","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1016\/j.bbagen.2014.06.004","article-title":"Combinatorial anticancer effects of curcumin and 5-fluorouracil loaded thiolated chitosan nanoparticles towards colon cancer treatment","volume":"1840","author":"Anitha","year":"2014","journal-title":"Corrigendum Biochim. Biophys. Acta Gen Subj."},{"issue":"39","key":"10.1016\/j.addr.2026.115957_bb0955","doi-asserted-by":"crossref","first-page":"7724","DOI":"10.1039\/C5TB01245G","article-title":"Co-delivery of camptothecin and curcumin by cationic polymeric nanoparticles for synergistic colon cancer combination chemotherapy","volume":"3","author":"Xiao","year":"2015","journal-title":"J. Mater. Chem. B"},{"issue":"3","key":"10.1016\/j.addr.2026.115957_bb0960","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1080\/1061186X.2022.2148679","article-title":"EpCAM aptamer activated 5-FU-loaded PLGA nanoparticles in CRC treatment; in vitro and in vivo study","volume":"31","author":"Yavari","year":"2023","journal-title":"J. Drug Target."},{"key":"10.1016\/j.addr.2026.115957_bb0670","doi-asserted-by":"crossref","DOI":"10.1177\/15347354221105498","article-title":"Long-term survival, tolerability, and safety of first-line bevacizumab and FOLFIRI in combination with ginsenoside-modified nanostructured lipid carrier containing curcumin in patients with unresectable metastatic colorectal cancer","volume":"21","author":"Jeon","year":"2022","journal-title":"Integr. Cancer Ther."},{"issue":"33","key":"10.1016\/j.addr.2026.115957_bb0525","doi-asserted-by":"crossref","first-page":"14080","DOI":"10.1039\/C5NR03527A","article-title":"Overcoming acquired drug resistance in colorectal cancer cells by targeted delivery of 5-FU with EGF grafted hollow mesoporous silica nanoparticles","volume":"7","author":"Chen","year":"2015","journal-title":"Nanoscale"},{"issue":"1","key":"10.1016\/j.addr.2026.115957_bb0780","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1186\/s12951-023-02157-x","article-title":"A carrier-free supramolecular nano-twin-drug for overcoming irinotecan-resistance and enhancing efficacy against colorectal cancer","volume":"21","author":"Yuan","year":"2023","journal-title":"J Nanobiotechnol."},{"issue":"2","key":"10.1016\/j.addr.2026.115957_bb0965","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","article-title":"Drug combination studies and their synergy quantification using the Chou-Talalay method","volume":"70","author":"Chou","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.addr.2026.115957_bb0970","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2021.670124","article-title":"Orally administrable therapeutic nanoparticles for the treatment of colorectal cancer","volume":"9","author":"Ying","year":"2021","journal-title":"Front. Bioeng. Biotechnol."},{"issue":"2","key":"10.1016\/j.addr.2026.115957_bb0405","article-title":"Minimal information for studies of extracellular vesicles (MISEV2023): from basic to advanced approaches","volume":"13","author":"Welsh","year":"2024","journal-title":"Correction J. Extracell. Vesicles"},{"key":"10.1016\/j.addr.2026.115957_bb0975","article-title":"Using magnetic mesoporous silica nanoparticles armed with EpCAM aptamer as an efficient platform for specific delivery of 5-fluorouracil to colorectal cancer cells","volume":"10","author":"Al-Mosawi","year":"2023","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/j.addr.2026.115957_bb0645","unstructured":"ClinicalTrials.gov, NCT01464593: Phase 2 Study of ThermoDox as Adjuvant Therapy With Thermal Ablation (RFA) in Treatment of Metastatic Colorectal Cancer (mCRC). Bethesda (MD): National Library of Medicine. https:\/\/clinicaltrials.gov\/study\/NCT01464593 (accessed 3 June 2026)."},{"key":"10.1016\/j.addr.2026.115957_bb0275","doi-asserted-by":"crossref","first-page":"3819","DOI":"10.2147\/IJN.S139450","article-title":"CPX-351: a nanoscale liposomal co-formulation of daunorubicin and cytarabine with unique biodistribution and tumor cell uptake properties","author":"Mayer","year":"2019","journal-title":"Int. J. Nanomedicine"},{"issue":"3","key":"10.1016\/j.addr.2026.115957_bb0280","doi-asserted-by":"crossref","first-page":"893","DOI":"10.3390\/pharmaceutics15030893","article-title":"Recent preclinical and clinical progress in liposomal doxorubicin","volume":"15","author":"Aloss","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.addr.2026.115957_bb0285","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jconrel.2021.05.012","article-title":"The reversal of chemotherapy-induced multidrug resistance by nanomedicine for cancer therapy","volume":"335","author":"Liu","year":"2021","journal-title":"J. Control. Release"},{"issue":"8","key":"10.1016\/j.addr.2026.115957_bb0290","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1039\/C9BM00355J","article-title":"A new insight into the reversal of multidrug resistance in cancer by nanodrugs","volume":"7","author":"Jiang","year":"2019","journal-title":"Biomater. Sci."},{"issue":"1","key":"10.1016\/j.addr.2026.115957_bb0295","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-022-01524-w","article-title":"CDK6-PI3K signaling axis is an efficient target for attenuating ABCB1\/P-gp mediated multi-drug resistance (MDR) in cancer cells","volume":"21","author":"Zhang","year":"2022","journal-title":"Mol. Cancer"},{"issue":"9","key":"10.1016\/j.addr.2026.115957_bb0300","doi-asserted-by":"crossref","first-page":"5505","DOI":"10.1021\/acs.chemrev.3c00705","article-title":"Polymeric nanoparticles for drug delivery","volume":"124","author":"Beach","year":"2024","journal-title":"Chem. Rev."},{"issue":"22","key":"10.1016\/j.addr.2026.115957_bb0305","doi-asserted-by":"crossref","first-page":"35583","DOI":"10.18632\/oncotarget.14709","article-title":"Biodegradable and biocompatible high elastic chitosan scaffold is cell-friendly both in vitro and in vivo","volume":"8","author":"Pang","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.addr.2026.115957_bb0310","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jconrel.2023.09.003","article-title":"Accelerated blood clearance of PEGylated nanoparticles induced by PEG-based pharmaceutical excipients","volume":"363","author":"Miao","year":"2023","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2026.115957_bb0315","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jconrel.2015.06.023","article-title":"The effect of polymer backbone chemistry on the induction of the accelerated blood clearance in polymer modified liposomes","volume":"213","author":"Kierstead","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2026.115957_bb0320","article-title":"Rational design and latest advances of codelivery systems for cancer therapy","volume":"7","author":"Meng","year":"2020","journal-title":"Mater. Today Bio"},{"issue":"6","key":"10.1016\/j.addr.2026.115957_bb0325","doi-asserted-by":"crossref","first-page":"672","DOI":"10.3390\/life14060672","article-title":"Targeted liposomal drug delivery: overview of the current applications and challenges","volume":"14","author":"Gatto","year":"2024","journal-title":"Life"},{"key":"10.1016\/j.addr.2026.115957_bb0330","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2024.124512","article-title":"Prediction and verification of targets for alpha-hederin\/oxaliplatin dual-loaded rHDL modified liposomes: reversing effector T-cells dysfunction and improving anti-COAD efficiency in vitro and in vivo","volume":"662","author":"Wang","year":"2024","journal-title":"Int. J. Pharm."},{"issue":"1","key":"10.1016\/j.addr.2026.115957_bb0335","first-page":"189","article-title":"Co-encapsulation of curcumin and salicylic acid in mucoadhesive polymer nanoparticles","volume":"14","author":"Moreno","year":"2024","journal-title":"J. Appl. Pharm. Sci."},{"key":"10.1016\/j.addr.2026.115957_bb0340","doi-asserted-by":"crossref","DOI":"10.1016\/j.foodchem.2019.125328","article-title":"Enhancing the oral bioavailability of curcumin using solid lipid nanoparticles","volume":"302","author":"Ban","year":"2020","journal-title":"Food Chem."},{"issue":"2","key":"10.1016\/j.addr.2026.115957_bb0345","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1080\/02726351.2025.2586036","article-title":"Fabrication of mesoporous silica-capped mesoporous carbon quantum dots nanoparticles: unveiling the potential effects of synergic chemo-photothermal in colorectal cancer therapy","volume":"44","author":"Liu","year":"2026","journal-title":"Part. Sci. Technol."},{"issue":"6","key":"10.1016\/j.addr.2026.115957_bb0350","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.tips.2022.03.003","article-title":"Supramolecular nanomedicines through rational design of self-assembling prodrugs","volume":"43","author":"Wang","year":"2022","journal-title":"Trends Pharmacol. Sci."},{"issue":"5","key":"10.1016\/j.addr.2026.115957_bb0355","doi-asserted-by":"crossref","first-page":"4564","DOI":"10.1021\/acsanm.3c03315","article-title":"Review of carrier-free self-assembly of anticancer nanodrugs","volume":"7","author":"Ji","year":"2024","journal-title":"ACS Appl. Nano Mater."},{"issue":"26","key":"10.1016\/j.addr.2026.115957_bb0360","doi-asserted-by":"crossref","DOI":"10.1002\/smll.202310838","article-title":"Self-assembled nanocarrier delivery systems for bioactive compounds","volume":"20","author":"Zhang","year":"2024","journal-title":"Small"},{"key":"10.1016\/j.addr.2026.115957_bb0365","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2025.113775","article-title":"Metal-phenolic networks reverse the immunosuppressive tumor microenvironment via dual metabolism regulation and immunogenic cell death","volume":"383","author":"Nam","year":"2025","journal-title":"J. Control. Release"},{"issue":"3","key":"10.1016\/j.addr.2026.115957_bb0370","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1080\/20415990.2025.2458449","article-title":"SN-38-indoximod conjugate: carrier free nano-prodrug for cancer therapy","volume":"16","author":"Kumar","year":"2025","journal-title":"Ther. Deliv."},{"issue":"9","key":"10.1016\/j.addr.2026.115957_bb0375","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13092058","article-title":"Nanomedicine to overcome multidrug resistance mechanisms in colon and pancreatic cancer: recent progress","volume":"13","author":"Ortiz","year":"2021","journal-title":"Cancers"},{"issue":"6","key":"10.1016\/j.addr.2026.115957_bb0380","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1039\/D3TB02393A","article-title":"\u0392-Glycosidase sensitive oral nanoparticles for combined photothermal and chemo treatment of colorectal cancer","volume":"12","author":"Zhou","year":"2024","journal-title":"J. Mater. Chem. B"},{"issue":"7","key":"10.1016\/j.addr.2026.115957_bb0385","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1158\/1535-7163.MCT-06-0118","article-title":"Ratiometric dosing of anticancer drug combinations: controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice","volume":"5","author":"Mayer","year":"2006","journal-title":"Mol. Cancer Ther."},{"issue":"3","key":"10.1016\/j.addr.2026.115957_bb0390","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1007\/s13346-024-01698-4","article-title":"Plant-derived extracellular vesicles: a synergetic combination of a drug delivery system and a source of natural bioactive compounds","volume":"15","author":"Langellotto","year":"2025","journal-title":"Drug Deliv. Transl. Res."},{"issue":"10","key":"10.1016\/j.addr.2026.115957_bb0395","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1038\/mt.2016.159","article-title":"Edible ginger-derived nano-lipids loaded with doxorubicin as a novel drug-delivery approach for colon cancer therapy","volume":"24","author":"Zhang","year":"2016","journal-title":"Mol. Ther."},{"key":"10.1016\/j.addr.2026.115957_bb0400","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2025.1587560","article-title":"Functionalized turmeric nanovesicles for precision delivery of doxorubicin in colorectal carcinoma treatment","volume":"16","author":"Meng","year":"2025","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.addr.2026.115957_bb0410","doi-asserted-by":"crossref","DOI":"10.1002\/VIW.20240115","article-title":"Plant-derived extracellular vesicles: current status and challenges for developing a new paradigm in therapeutics development","volume":"6","author":"Jo","year":"2025","journal-title":"View"},{"issue":"12","key":"10.1016\/j.addr.2026.115957_bb0415","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpha.2024.101049","article-title":"Recent advances in bacterial outer membrane vesicles: effects on the immune system, mechanisms and their usage for tumor treatment","volume":"14","author":"Xiang","year":"2024","journal-title":"J. Pharm. Anal."},{"key":"10.1016\/j.addr.2026.115957_bb0420","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.omto.2022.12.002","article-title":"A cancer cell membrane coated, doxorubicin and microRNA co-encapsulated nanoplatform for colorectal cancer theranostics","volume":"28","author":"Zhu","year":"2023","journal-title":"Mol. Therapy-Oncolytics"},{"issue":"23","key":"10.1016\/j.addr.2026.115957_bb0425","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.2217\/nnm-2023-0145","article-title":"CD44 targeted delivery of hyaluronic acid-coated polymeric nanoparticles against colorectal cancer","volume":"18","author":"Phatak","year":"2023","journal-title":"Nanomedicine"},{"key":"10.1016\/j.addr.2026.115957_bb0430","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.jconrel.2024.10.043","article-title":"A pH and glutathione-responsive carbon monoxide-driven nano-herb delivery system for enhanced immunotherapy in colorectal cancer","volume":"376","author":"Yang","year":"2024","journal-title":"J. Control. Release"},{"issue":"24","key":"10.1016\/j.addr.2026.115957_bb0435","doi-asserted-by":"crossref","first-page":"7458","DOI":"10.7150\/thno.38081","article-title":"Orally deliverable nanotherapeutics for the synergistic treatment of colitis-associated colorectal cancer","volume":"9","author":"Han","year":"2019","journal-title":"Theranostics"},{"issue":"3","key":"10.1016\/j.addr.2026.115957_bb0440","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ejps.2011.04.011","volume":"43","author":"Sun","year":"2011","journal-title":"Eur. J. Pharm. Sci."},{"issue":"4","key":"10.1016\/j.addr.2026.115957_bb0445","doi-asserted-by":"crossref","first-page":"3004","DOI":"10.1245\/s10434-025-18874-6","article-title":"Absolute bioavailability of oxaliplatin after intraperitoneal administration by electrostatic pressurized intraperitoneal aerosol chemotherapy (ePIPAC): systemic pharmacokinetics of the CRC-PIPAC-II trial","volume":"33","author":"van den Heuvel","year":"2026","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.addr.2026.115957_bb0450","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jconrel.2024.07.017","article-title":"Intraperitoneal drug delivery systems for peritoneal carcinomatosis: bridging the gap between research and clinical implementation","volume":"373","author":"Perell\u00f3-Trias","year":"2024","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2026.115957_bb0455","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2023.176013","article-title":"Cancer chemotherapy resistance: mechanisms and recent breakthrough in targeted drug delivery","volume":"958","author":"Davodabadi","year":"2023","journal-title":"Eur. J. Pharmacol."},{"issue":"6","key":"10.1016\/j.addr.2026.115957_bb0460","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.21037\/jgo-24-515","article-title":"Establishing a standardized murine orthotopic intra-rectal model for the study of colorectal adenocarcinoma","volume":"15","author":"Cyr","year":"2024","journal-title":"J. Gastrointestinal Oncol."},{"issue":"1","key":"10.1016\/j.addr.2026.115957_bb0465","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.neo.2020.11.005","article-title":"Patient-derived xenograft (PDX) models of colorectal carcinoma (CRC) as a platform for chemosensitivity and biomarker analysis in personalized medicine","volume":"23","author":"Rivera","year":"2021","journal-title":"Neoplasia"},{"issue":"2","key":"10.1016\/j.addr.2026.115957_bb0470","doi-asserted-by":"crossref","first-page":"409","DOI":"10.37349\/etat.2024.00226","article-title":"Spheroids and organoids derived from colorectal cancer as tools for in vitro drug screening","volume":"5","author":"Zawawi","year":"2024","journal-title":"Exploration Targeted Anti-tumor Therapy"},{"issue":"40","key":"10.1016\/j.addr.2026.115957_bb0475","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2507922122","article-title":"Influence of the protein corona on hematopoietic stem and progenitor cell uptake and macrophage clearance of membrane-wrapped nanoparticles","volume":"122","author":"Sterin","year":"2025","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"26","key":"10.1016\/j.addr.2026.115957_bb0480","doi-asserted-by":"crossref","first-page":"37383","DOI":"10.1021\/acsami.5c07366","article-title":"The nanocarrier landscapeevaluating key drug delivery vehicles and their capabilities: a translational perspective","volume":"17","author":"Khalid-Salako","year":"2025","journal-title":"ACS Appl. Mater. Interfaces"},{"issue":"3","key":"10.1016\/j.addr.2026.115957_bb0485","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.149","article-title":"Analysis of drug combinations: current methodological landscape","volume":"3","author":"Foucquier","year":"2015","journal-title":"Pharmacol. Res. Perspect."},{"key":"10.1016\/j.addr.2026.115957_bb0490","article-title":"Intraperitoneal administration of cabazitaxel-loaded nanoparticles in peritoneal metastasis models","volume":"48","author":"Hyldbakk","year":"2023","journal-title":"Nanomedicine"},{"issue":"1","key":"10.1016\/j.addr.2026.115957_bb0495","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1186\/s12951-025-03417-8","article-title":"Oxygen vacancy-engineered bimetallic nanozymes for disrupting electron transport chain and synergistic multi-enzyme activity to reverse oxaliplatin resistance in colorectal cancer","volume":"23","author":"Zhong","year":"2025","journal-title":"J Nanobiotechnol."},{"issue":"2","key":"10.1016\/j.addr.2026.115957_bb0500","article-title":"Codelivery of apigenin, FdUMP and CD276 antibody synergistic inhibit colorectal cancer by ferroptosis-apoptosis-pyroptosis and CD276 blockade","volume":"20","author":"Cao","year":"2025","journal-title":"Asian J Pharm Sci"},{"key":"10.1016\/j.addr.2026.115957_bb0505","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2025.118565","article-title":"TME-responsive nanoparticles co-targeting VCP, NETs, and dual immune checkpoints for immune revitalization in EGFR\/PD-L1\/CTLA-4-driven colorectal cancer","volume":"192","author":"Lo","year":"2025","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.addr.2026.115957_bb0510","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.actbio.2024.06.042","article-title":"Antibacterial tellurium-containing polycarbonate drug carriers to eliminate intratumor bacteria for synergetic chemotherapy against colorectal cancer","volume":"185","author":"Hu","year":"2024","journal-title":"Acta Biomater."},{"issue":"2","key":"10.1016\/j.addr.2026.115957_bb0515","doi-asserted-by":"crossref","first-page":"314","DOI":"10.3390\/pharmaceutics15020314","article-title":"Synergistic antitumor potency of a self-assembling cyclodextrin nanoplex for the co-delivery of 5-fluorouracil and interleukin-2 in the treatment of colorectal cancer","volume":"15","author":"Akkin","year":"2023","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.addr.2026.115957_bb0520","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/s10856-023-06766-8","article-title":"Oxali-palladium nanoparticle synthesis, characterization, protein binding, and apoptosis induction in colorectal cancer cells","volume":"35","author":"Golestannezhad","year":"2024","journal-title":"J. Mater. Sci. Mater. Med."},{"key":"10.1016\/j.addr.2026.115957_bb0530","first-page":"126","article-title":"CRCs-CAFs crosstalk-targeted nano-delivery system reprograms tumor microenvironment for oxaliplatin resistance reversing and liver metastasis inhibition in colorectal cancer","volume":"54","author":"Liu","year":"2025","journal-title":"Bioact. Mater."},{"key":"10.1016\/j.addr.2026.115957_bb0535","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2022.121827","article-title":"Precision medicine-guided co-delivery of ASPN siRNA and oxaliplatin by nanoparticles to overcome chemoresistance of colorectal cancer","volume":"290","author":"Huang","year":"2022","journal-title":"Biomaterials"},{"issue":"1","key":"10.1016\/j.addr.2026.115957_bb0700","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1186\/s12951-025-03422-x","article-title":"Automatic target-seeking nanoparticle inhibiting orthotopic drug-resistant colon cancer and liver metastases via regulating cancer cell adhesion and proliferation","volume":"23","author":"Bai","year":"2025","journal-title":"J Nanobiotechnol."},{"issue":"1","key":"10.1016\/j.addr.2026.115957_bb0785","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1080\/10717544.2021.1914777","article-title":"Novel hyaluronic acid oligosaccharide-loaded and CD44v6-targeting oxaliplatin nanoparticles for the treatment of colorectal cancer","volume":"28","author":"Du","year":"2021","journal-title":"Drug Deliv."},{"issue":"38","key":"10.1016\/j.addr.2026.115957_bb0540","article-title":"The in vivo biological fate of protein corona: a comparative pet study of the fate of soft and hard protein corona in healthy animal models","volume":"20","author":"Villacorta","year":"2024","journal-title":"Small"},{"key":"10.1016\/j.addr.2026.115957_bb0545","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.jconrel.2021.08.048","article-title":"Complement opsonization of nanoparticles: differences between humans and preclinical species","volume":"338","author":"Li","year":"2021","journal-title":"J. Control. Release"},{"issue":"43","key":"10.1016\/j.addr.2026.115957_bb0550","doi-asserted-by":"crossref","first-page":"17342","DOI":"10.1039\/D3NR03823H","article-title":"Competition of opsonins and dysopsonins on the nanoparticle surface","volume":"15","author":"Tavakol","year":"2023","journal-title":"Nanoscale"},{"issue":"1","key":"10.1016\/j.addr.2026.115957_bb0555","doi-asserted-by":"crossref","first-page":"8699","DOI":"10.1038\/s41467-025-63726-2","article-title":"Protein corona formed on lipid nanoparticles compromises delivery efficiency of mRNA cargo","volume":"16","author":"Voke","year":"2025","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.addr.2026.115957_bb0560","first-page":"401","article-title":"Changes in target ability of nanoparticles due to protein corona composition and disease state","volume":"17","author":"Xu","year":"2022","journal-title":"Asian J. Pharmaceutical Sci."},{"issue":"1","key":"10.1016\/j.addr.2026.115957_bb0565","doi-asserted-by":"crossref","first-page":"4366","DOI":"10.1038\/s41467-024-48838-5","article-title":"Rediscovery of mononuclear phagocyte system blockade for nanoparticle drug delivery","volume":"15","author":"Zelepukin","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.addr.2026.115957_bb0570","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.jconrel.2024.03.052","article-title":"Nanodrug modified with engineered cell membrane targets CDKs to activate aPD-L1 immunotherapy against liver metastasis of immune-desert colon cancer","volume":"369","author":"Ding","year":"2024","journal-title":"J. Control. Release"},{"issue":"1","key":"10.1016\/j.addr.2026.115957_bb0575","article-title":"Advanced strategies to evade the mononuclear phagocyte system clearance of nanomaterials","volume":"3","author":"Lu","year":"2023","journal-title":"Exploration (Beijing)"},{"issue":"3","key":"10.1016\/j.addr.2026.115957_bb0580","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01692-24","article-title":"Liposomal amphotericin B and complement activation-related pseudoallergy (CARPA)","volume":"69","author":"Thompson","year":"2025","journal-title":"Antimicrob. Agents Chemother."},{"issue":"42","key":"10.1016\/j.addr.2026.115957_bb0585","doi-asserted-by":"crossref","first-page":"28649","DOI":"10.1021\/acsnano.4c05087","article-title":"Nanoparticle-binding immunoglobulins predict variable complement responses in healthy and diseased cohorts","volume":"18","author":"Li","year":"2024","journal-title":"ACS Nano"},{"key":"10.1016\/j.addr.2026.115957_bb0590","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2025.113821","article-title":"Impact of pre-existing anti-polyethylene glycol (PEG) IgM on biodistribution and humoral response of intramuscularly administered PEGylated mRNA loaded lipid nanoparticle","volume":"383","author":"Abe","year":"2025","journal-title":"J. Control. Release"},{"issue":"3","key":"10.1016\/j.addr.2026.115957_bb0595","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1039\/D2BM01404A","article-title":"Mucus-penetrating dendritic mesoporous silica nanoparticle loading drug nanocrystal clusters to enhance permeation and intestinal absorption","volume":"11","author":"Zhou","year":"2023","journal-title":"Biomater. Sci."},{"issue":"9","key":"10.1016\/j.addr.2026.115957_bb0600","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1039\/D2TB02253B","article-title":"Cancer-associated fibroblast-targeted nanodrugs reshape colorectal tumor microenvironments to suppress tumor proliferation, metastasis and improve drug penetration","volume":"11","author":"Shen","year":"2023","journal-title":"J. Mater. Chem. B"},{"issue":"29","key":"10.1016\/j.addr.2026.115957_bb0605","doi-asserted-by":"crossref","first-page":"18963","DOI":"10.1021\/acsnano.4c02312","article-title":"Injectable nanocomposite hydrogels improve intraperitoneal co-delivery of chemotherapeutics and immune checkpoint inhibitors for enhanced peritoneal metastasis therapy","volume":"18","author":"Liang","year":"2024","journal-title":"ACS Nano"},{"issue":"13","key":"10.1016\/j.addr.2026.115957_bb0610","doi-asserted-by":"crossref","first-page":"13381","DOI":"10.1021\/acsnano.5c01399","article-title":"Iron homeostasis-regulated adaptive metabolism of pegylated ultrasmall iron oxide nanoparticles","volume":"19","author":"Wang","year":"2025","journal-title":"ACS Nano"},{"key":"10.1016\/j.addr.2026.115957_bb0615","doi-asserted-by":"crossref","first-page":"4103","DOI":"10.2147\/IJN.S443168","article-title":"Long-term accumulation, biological effects and toxicity of BSA-coated gold nanoparticles in the mouse liver, spleen, and kidneys","author":"Jakic","year":"2024","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.addr.2026.115957_bb0620","article-title":"Recent advanced lipid-based nanomedicines for overcoming cancer resistance","volume":"7","author":"Dechbumroong","year":"2024","journal-title":"Cancer Drug Resist."},{"issue":"33","key":"10.1016\/j.addr.2026.115957_bb0625","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202403199","article-title":"Immunogenicity of extracellular vesicles","volume":"36","author":"Xia","year":"2024","journal-title":"Adv. Mater."},{"issue":"14","key":"10.1016\/j.addr.2026.115957_bb0630","doi-asserted-by":"crossref","first-page":"6045","DOI":"10.1039\/C5NR00733J","article-title":"Interactions of PLGA nanoparticles with blood components: protein adsorption, coagulation, activation of the complement system and hemolysis studies","volume":"7","author":"Fornaguera","year":"2015","journal-title":"Nanoscale"},{"key":"10.1016\/j.addr.2026.115957_bb0685","series-title":"Drug Products, Including Biological Products, that Contain Nanomaterials: Guidance for Industry","author":"U.S. Food and Drug Administration","year":"2022"},{"key":"10.1016\/j.addr.2026.115957_bb0980","series-title":"National Cancer Institute, NCL Assay Cascade Protocols and Capabilities","author":"Nanotechnology Characterization Laboratory","year":"2026"},{"key":"10.1016\/j.addr.2026.115957_bb0985","series-title":"Liposome Drug Products: Chemistry, Manufacturing, and Controls; Human Pharmacokinetics and Bioavailability; and Labeling Documentation: Guidance for Industry","author":"U.S. Food and Drug Administration","year":"2018"},{"key":"10.1016\/j.addr.2026.115957_bb0990","series-title":"General Chapter <85>: Bacterial Endotoxins Test","author":"United States Pharmacopeia","year":"2026"},{"key":"10.1016\/j.addr.2026.115957_bb0995","series-title":"ICH Q8(R2), Q9(R1), Q10 and Q12 Quality Guidelines","author":"International Council for Harmonisation","year":"2023"},{"issue":"10","key":"10.1016\/j.addr.2026.115957_bb1000","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1038\/nnano.2013.181","article-title":"Rapid formation of plasma protein corona critically affects nanoparticle pathophysiology","volume":"8","author":"Tenzer","year":"2013","journal-title":"Nat. Nanotechnol."},{"issue":"25","key":"10.1016\/j.addr.2026.115957_bb1005","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1039\/c3cc37307j","article-title":"Protein corona significantly reduces active targeting yield","volume":"49","author":"Mirshafiee","year":"2013","journal-title":"Chem. Commun. (Camb.)"},{"issue":"8","key":"10.1016\/j.addr.2026.115957_bb1010","doi-asserted-by":"crossref","first-page":"8142","DOI":"10.1021\/acsnano.5b03300","article-title":"In vivo biomolecule corona around blood-circulating, clinically used and antibody-targeted lipid bilayer nanoscale vesicles","volume":"9","author":"Hadjidemetriou","year":"2015","journal-title":"ACS Nano"},{"issue":"4","key":"10.1016\/j.addr.2026.115957_bb1015","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1038\/nnano.2015.330","article-title":"Protein adsorption is required for stealth effect of poly(ethylene glycol)- and poly(phosphoester)-coated nanocarriers","volume":"11","author":"Sch\u00f6ttler","year":"2016","journal-title":"Nat. Nanotechnol."},{"issue":"6","key":"10.1016\/j.addr.2026.115957_bb1020","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1615\/CritRevTherDrugCarrierSyst.v18.i6.50","article-title":"Complement activation-related pseudoallergy caused by liposomes, micellar carriers of intravenous drugs, and radiocontrast agents","volume":"18","author":"Szebeni","year":"2001","journal-title":"Crit. Rev. Ther. Drug Carrier Syst."},{"issue":"2","key":"10.1016\/j.addr.2026.115957_bb1025","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.molimm.2014.06.038","article-title":"Complement activation-related pseudoallergy: a stress reaction in blood triggered by nanomedicines and biologicals","volume":"61","author":"Szebeni","year":"2014","journal-title":"Mol. Immunol."},{"issue":"1","key":"10.1016\/j.addr.2026.115957_bb1030","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jconrel.2013.07.026","article-title":"The accelerated blood clearance (ABC) phenomenon: clinical challenge and approaches to manage","volume":"172","author":"Abu Lila","year":"2013","journal-title":"J. Control. Release"},{"issue":"9","key":"10.1016\/j.addr.2026.115957_bb1035","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.tcb.2011.06.002","article-title":"Biological hydrogels as selective diffusion barriers","volume":"21","author":"Lieleg","year":"2011","journal-title":"Trends Cell Biol."},{"issue":"14","key":"10.1016\/j.addr.2026.115957_bb1040","doi-asserted-by":"crossref","first-page":"4218","DOI":"10.1039\/C6CS00636A","article-title":"Cellular uptake of nanoparticles: journey inside the cell","volume":"46","author":"Behzadi","year":"2017","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.addr.2026.115957_bb1045","doi-asserted-by":"crossref","first-page":"16014","DOI":"10.1038\/natrevmats.2016.14","article-title":"Analysis of nanoparticle delivery to tumours","volume":"1","author":"Wilhelm","year":"2016","journal-title":"Nat. Rev. Mater."},{"issue":"7","key":"10.1016\/j.addr.2026.115957_bb1050","doi-asserted-by":"crossref","first-page":"8023","DOI":"10.1021\/acsnano.9b02774","article-title":"Supervised learning and mass spectrometry predicts the in vivo fate of nanomaterials","volume":"13","author":"Lazarovits","year":"2019","journal-title":"ACS Nano"},{"key":"10.1016\/j.addr.2026.115957_bb1055","series-title":"Biological Evaluation of Medical Devices \u2014 Part 22: Guidance on Nanomaterials","author":"International Organization for Standardization","year":"2017"},{"key":"10.1016\/j.addr.2026.115957_bb1060","series-title":"M3(R2): Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals","author":"International Council for Harmonisation","year":"2009"},{"key":"10.1016\/j.addr.2026.115957_bb1065","series-title":"S8: Immunotoxicity Studies for Human Pharmaceuticals","author":"International Council for Harmonisation","year":"2005"},{"issue":"4","key":"10.1016\/j.addr.2026.115957_bb1070","first-page":"5239","article-title":"Scientific opinion on the safety of green tea catechins","volume":"16","author":"Younes","year":"2018","journal-title":"EFSA J."},{"issue":"1","key":"10.1016\/j.addr.2026.115957_bb0635","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.apsb.2024.12.007","article-title":"Recent advances in the bench-to-bedside translation of cancer nanomedicines","volume":"15","author":"Liu","year":"2025","journal-title":"Acta Pharmaceutica Sinica B"},{"issue":"2D","key":"10.1016\/j.addr.2026.115957_bb1075","doi-asserted-by":"crossref","DOI":"10.6004\/jnccn.2024.0029","article-title":"Colon cancer, version 3.2024, NCCN clinical practice guidelines in oncology","volume":"22","author":"Benson","year":"2024","journal-title":"J. Natl. Compr. Canc. Netw."},{"issue":"15","key":"10.1016\/j.addr.2026.115957_bb1080","doi-asserted-by":"crossref","first-page":"4190","DOI":"10.1158\/1078-0432.CCR-16-3193","article-title":"64Cu-MM-302 positron emission tomography quantifies variability of enhanced permeability and retention of nanoparticles in relation to treatment response in patients with metastatic breast cancer","volume":"23","author":"Lee","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.addr.2026.115957_bb1085","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.addr.2018.07.007","article-title":"Tumor targeting via EPR: strategies to enhance patient responses","volume":"130","author":"Golombek","year":"2018","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"10409","key":"10.1016\/j.addr.2026.115957_bb0640","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1016\/S0140-6736(23)01366-1","article-title":"NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial","volume":"402","author":"Wainberg","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.addr.2026.115957_bb0650","article-title":"FOLFOXIRI plus cetuximab as conversion therapy for unresectable RAS\/BRAF wild-type left-sided colorectal cancer with liver-limited metastases: a prospective dual-center pilot study","volume":"14","author":"Yang","year":"2024","journal-title":"Front. Oncol."},{"issue":"3","key":"10.1016\/j.addr.2026.115957_bb0655","doi-asserted-by":"crossref","DOI":"10.1093\/oncolo\/oyae360","article-title":"Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer: safety analysis of FRESCO-2","volume":"30","author":"Eng","year":"2025","journal-title":"Oncologist"},{"issue":"6","key":"10.1016\/j.addr.2026.115957_bb0660","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.21037\/jgo-22-259","article-title":"A phase II randomized double blinded trial evaluating the efficacy of curcumin with pre-operative chemoradiation for rectal cancer","volume":"13","author":"Gunther","year":"2022","journal-title":"J. Gastrointest Oncol."},{"issue":"7","key":"10.1016\/j.addr.2026.115957_bb0665","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1093\/jn\/nxz029","article-title":"Curcumin combined with FOLFOX chemotherapy is safe and tolerable in patients with metastatic colorectal cancer in a randomized phase IIa trial","volume":"149","author":"Howells","year":"2019","journal-title":"J. Nutr."},{"key":"10.1016\/j.addr.2026.115957_bb0675","series-title":"NCT01294072: Study Investigating the Ability of Plant Exosomes to Deliver Curcumin to Normal and Colon Cancer Tissue","author":"ClinicalTrials.gov","year":"2026"},{"key":"10.1016\/j.addr.2026.115957_bb0680","series-title":"NCT05854498: Phase II Study of Liposomal Irinotecan With TAS102 and Bevacizumab for Patients With Metastatic Colorectal Cancer","author":"ClinicalTrials.gov","year":"2026"},{"key":"10.1016\/j.addr.2026.115957_bb0690","author":"ClinicalTrials.gov"},{"key":"10.1016\/j.addr.2026.115957_bb0695","series-title":"NCT05631041: The Possible Anticancer Effect of Silymarin in Patients With Metastatic Colorectal Cancer Receiving Chemotherapy","author":"ClinicalTrials.gov","year":"2026"},{"issue":"8","key":"10.1016\/j.addr.2026.115957_bb0705","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1038\/s41416-024-02826-0","article-title":"Consensus molecular subtyping of metastatic colorectal cancer expands biomarker-directed therapeutic benefit for patients with CMS1 and CMS2 tumors","volume":"131","author":"Chowdhury","year":"2024","journal-title":"Br. J. Cancer"},{"issue":"2","key":"10.1016\/j.addr.2026.115957_bb0710","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/s41419-018-1285-3","article-title":"Nanoparticle enhanced MRI can monitor macrophage response to CD47 mAb immunotherapy in osteosarcoma","volume":"10","author":"Mohanty","year":"2019","journal-title":"Cell Death Dis."},{"issue":"1","key":"10.1016\/j.addr.2026.115957_bb0715","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1148\/radiol.2020201791","article-title":"Detecting immune response to therapies targeting PDL1 and BRAF by using ferumoxytol MRI and macrin in anaplastic thyroid cancer","volume":"298","author":"Ng","year":"2021","journal-title":"Radiology"},{"issue":"3","key":"10.1016\/j.addr.2026.115957_bb0720","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1007\/s13346-020-00744-1","article-title":"Critical quality attributes in the development of therapeutic nanomedicines toward clinical translation","volume":"10","author":"Taha","year":"2020","journal-title":"Drug Deliv. Transl. Res."},{"issue":"42","key":"10.1016\/j.addr.2026.115957_bb0725","doi-asserted-by":"crossref","first-page":"49022","DOI":"10.1021\/acsami.3c11274","article-title":"CO2-driven nebulization of pH-sensitive supramolecular polymers for intraperitoneal hydrogel formation and the treatment of peritoneal metastasis","volume":"15","author":"Braet","year":"2023","journal-title":"ACS Appl. Mater. Interfaces"},{"issue":"20","key":"10.1016\/j.addr.2026.115957_bb0730","doi-asserted-by":"crossref","first-page":"19810","DOI":"10.1021\/acsnano.3c04037","article-title":"Meta-analysis of nanoparticle distribution in tumors and major organs in tumor-bearing mice","volume":"17","author":"Chen","year":"2023","journal-title":"ACS Nano"},{"issue":"3","key":"10.1016\/j.addr.2026.115957_bb0735","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1007\/s13346-021-01024-2","article-title":"Current hurdles to the translation of nanomedicines from bench to the clinic","volume":"12","author":"\u0110or\u0111evi\u0107","year":"2022","journal-title":"Drug Deliv. Transl. Res."},{"issue":"16","key":"10.1016\/j.addr.2026.115957_bb0740","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.4155\/fmc.11.149","article-title":"Drug-permeability and transporter assays in Caco-2 and MDCK cell lines","volume":"3","author":"Volpe","year":"2011","journal-title":"Future Med. Chem."},{"issue":"3","key":"10.1016\/j.addr.2026.115957_bb0745","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.101198","article-title":"Establishment of patient-derived tumor organoids to functionally inform treatment decisions in metastatic colorectal cancer","volume":"8","author":"Martini","year":"2023","journal-title":"ESMO open"},{"issue":"45","key":"10.1016\/j.addr.2026.115957_bb0750","doi-asserted-by":"crossref","first-page":"21011","DOI":"10.1039\/D4NR02821J","article-title":"Interlaboratory comparison of endotoxin contamination assessment of nanomaterials","volume":"16","author":"Hannon","year":"2024","journal-title":"Nanoscale"},{"issue":"2","key":"10.1016\/j.addr.2026.115957_bb0755","doi-asserted-by":"crossref","first-page":"200","DOI":"10.3390\/vaccines12020200","article-title":"Edible plant-derived extracellular vesicles for oral mRNA vaccine delivery","volume":"12","author":"Gai","year":"2024","journal-title":"Vaccines"},{"key":"10.1016\/j.addr.2026.115957_bb0760","article-title":"Towards principled design of cancer nanomedicine to accelerate clinical translation","volume":"13","author":"Souri","year":"2022","journal-title":"Mater. Today Bio"},{"issue":"14","key":"10.1016\/j.addr.2026.115957_bb0765","doi-asserted-by":"crossref","first-page":"5643","DOI":"10.7150\/thno.97139","article-title":"Engineered plant-derived extracellular vesicles for targeted regulation and treatment of colitis-associated inflammation","volume":"14","author":"Kang","year":"2024","journal-title":"Theranostics"}],"container-title":["Advanced Drug Delivery Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X26001912?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X26001912?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T10:17:10Z","timestamp":1789121830000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169409X26001912"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":217,"alternative-id":["S0169409X26001912"],"URL":"https:\/\/doi.org\/10.1016\/j.addr.2026.115957","relation":{},"ISSN":["0169-409X"],"issn-type":[{"value":"0169-409X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bioactive nanomedicines for multidrug-resistant colorectal cancer: Actionable mechanisms, emerging particle classes, and translational barriers","name":"articletitle","label":"Article Title"},{"value":"Advanced Drug Delivery Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.addr.2026.115957","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"115957"}}